A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
The kidney is a vital organ with a variety of responsibilities. It plays an important role in maintaining the water, electrolyte and acid-base balance. It excretes toxic metabolic degradation products such as urea. It also recovers valuable substances such as glucose, amino acids, peptides and minerals initially filtered out of the blood during ultrafiltration in the renal corpuscles. In addition, endogenous and exogenous substances are metabolized and broken down in the kidneys—the kidney is therefore a central metabolic organ alongside the liver. Finally, some hormone-active substances are secreted by the kidney, such as renin, erythropoietin and calcitriol (active form of vitamin D3). As a result, the organ plays an important role in the regulation of blood pressure, new blood formation and the balance of calcium and phosphorus, and is thus crucial to bone metabolism, as well. As carnivores, cats are particularly dependent on the intake of animal proteins because glucose formation from amino acids is their most important energy source. The enzymes of amino acid degradation are adapted to the high protein intake and their activity is largely independent of the protein supply in the diet, so that cats break down endogenous proteins (especially from the muscles) when there is a lack of protein intake (catabolic metabolic state). Meat and offal also contain vital nutrients for the cat, such as Vitamin A, Taurin or arachidonic acid. Compared to a normal human diet, cats consume around six times as much phosphate in their diet with standard cat food.
Limosilactobacillus fermentum is a Gram-positive species in the heterofermentative genus Limosilactobacillus. It is associated with active dental caries lesions. It is also commonly found in fermenting animal and plant material including sourdough and cocoa fermentation. Some strains of lactobacilli formerly mistakenly classified as L. fermentum (such as RC-14) have since been reclassified as Limosilactobacillus reuteri.
239Pu is one of the three fissile materials used for the production of nuclear weapons and in some nuclear reactors as a source of energy. The other fissile materials are uranium-235 and uranium-233. 239Pu is virtually nonexistent in nature. It is made by bombarding uranium-238 with neutrons. Uranium-238 is present in quantity in most reactor fuel; hence 239Pu is continuously made in these reactors. Since 239Pu can itself be split by neutrons to release energy, 239Pu provides a portion of the energy generation in a nuclear reactor.
Synthetic biology can be used for creating nanoparticles which can be used for drug-delivery as well as for other purposes. Complementing research and development seeks to and has created synthetic cells that mimics functions of biological cells. Applications include medicine such as designer-nanoparticles that make blood cells eat away—from the inside out—portions of atherosclerotic plaque that cause heart attacks. Synthetic micro-droplets for algal cells or synergistic algal-bacterial multicellular spheroid microbial reactors, for example, could be used to produce hydrogen as hydrogen economy biotechnology.
== Structure == Most sv-LAAOs are reported as being homodimers with multiple subunits that have molecular weights around 50–70 kDa and the interaction between the subunits occurs via non-covalent interactions. Sv-LAAOs are present in the acidic, basic, and neutral forms of the protein. Studies that look at x-ray crystal structures have confirmed that sv-LAAOs are often found as functional dimers, with each dimer having three domains. The three domains are the substrate-binding site, FAD-binding site, and a helical domain. The substrate-binding site lies at the bottom of a funnel-shaped cavity approximately 25 Å deep, enabling substrate specificity among sv-LAAOs. Structural differences in active site topology likely account for species-dependent substrate preferences. Additionally, LAAOs are thermolabile, with cold inactivation and heat reactivation properties, necessitating specific storage and pre-activation conditions to preserve enzymatic activity. It has also been determined that the FAD prosthetic group becomes deeply entrenched in the enzyme structure, which allows for pervasive interactions with both neighboring atoms and conserved water molecules. Additionally, this flavin-containing prosthetic group has been classified as providing snake venom with its quintessential dark yellow coloration, which is shown in Figure 2. One unusual characteristic reported for sv-LAAOs regards the cold inactivation and heat reactivation properties of the protein. Thereby, most sv-LAAOs are considered to be thermolabile enzymes.
Sources: en.wikipedia.org
This reaction is strongly exothermic, so the equilibrium constant decreases with temperature. However, a temperature of around 400 °C is required in order to achieve a reasonable rate of reaction with currently available catalysts. Formation of ammonia is also favoured by high pressure, as the volume decreases when the reaction takes place. The same reaction, nitrogen fixation, occurs at ambient temperatures in nature, when the catalyst is an enzyme such as nitrogenase. Much energy is needed initially to break the nitrogen–nitrogen triple bond even though the overall reaction is exothermic. Gas-phase equilibria occur during combustion and were studied as early as 1943 in connection with the development of the V2 rocket engine. The calculation of composition for a gaseous equilibrium at constant pressure is often carried out using ΔG values, rather than equilibrium constants.
Vitamin D toxicity, or hypervitaminosis D, is the toxic state of an excess of vitamin D. It is rare, having occurred historically during a time of unregulated fortification of foods, especially those provided to infants, or more recently, with consumption of high-dose vitamin D dietary supplements following inappropriate prescribing, non-prescribed consumption of high-dose, over-the-counter preparations, or manufacturing errors resulting in content far in excess of what is on the label. Ultraviolet light alone – sunlight or tanning beds – can raise serum 25(OH)D concentration to a bit higher than 100 nmol/L, but not to a level that causes hypervitaminosis D, the reasons being that there is a limiting amount of the precursor 7-dehydrocholesterol synthesized in the skin and a negative feedback in the kidney wherein the presence of calcitriol induces diversion to metabolically inactive 24,25-hydroxyvitamin D rather than metabolically active calcitriol (1,25-hydroxyvitamin D). Further metabolism yields calcitroic acid, an inactive water-soluble compound that is excreted in bile. There is no general agreement about the intake levels at which vitamin D may cause harm. According to the IOM review, "Doses below 10,000 IU/day are not usually associated with toxicity, whereas doses equal to or above 50,000 IU/day for several weeks or months are frequently associated with toxic side effects including documented hypercalcemia." The normal range for blood concentration of 25-hydroxyvitamin D in adults is 20 to 50 nanograms per milliliter (ng/mL; equivalent to 50 to 125 nmol/L).
== See also == Controlled Substances Act Controlled Substance Analogue Enforcement of 1986 Controlled Drugs and Substances Act Lizard Labs New chemical entity Online illicit drug vendor Operation Web Tryp Federal Analogue Act Pharmaceutical company Psychoactive Substances Act 2013 – New Zealand Psychoactive Substances Act 2016 – UK ban on all drugs based on psychoactive effect PsychonautWiki Research chemical
Nicola Mary Turner is a New Zealand public health advocate who is a professor at the University of Auckland and medical director of the Immunisation Advisory Centre, an organisation that advises the New Zealand medical profession and the New Zealand Government. She has contributed to advisory committees for the New Zealand Ministry of Health, is a spokesperson for the Child Poverty Action Group (Aotearoa New Zealand) and works in general practice. Much of her research and outreach has focused on improving immunisation coverage and closing equity gaps for the national schedule vaccine delivery in New Zealand and she has commented publicly on these issues during COVID-19 pandemic in New Zealand.
Sources: en.wikipedia.org
=== Viral infections === Increased blood CRP levels were higher in people with avian flu H7N9 compared to those with H1N1 (more common) influenza, with a review reporting that severe H1N1 influenza had elevated CRP. In 2020, people infected with COVID-19 in Wuhan, China, had elevated CRP.
== M == MIKES – Mass-analyzed ion kinetic energy spectrometry MS – Mass spectrometer MS – Mass spectrometry MS2 – Mass spectrometry/mass spectrometry, i.e. tandem mass spectrometry MS/MS – Mass spectrometry/mass spectrometry, i.e. tandem mass spectrometry MALDESI – Matrix-assisted laser desorption electrospray ionization MALDI – Matrix-assisted laser desorption/ionization MAII – Matrix-assisted inlet ionization MAIV – Matrix-assisted ionization vacuum MIMS – Membrane introduction mass spectrometry, membrane inlet mass spectrometry, membrane interface mass spectrometry MCP – Microchannel plate MSn – Multiple-stage mass spectrometry MCP – Microchannel plate MPI – Multiphoton ionization MRM – Multiple reaction monitoring
Dizziness Fatigue Low blood pressure Diarrhea Weakness Slowed heart rate Weight gain Erectile dysfunction Carvedilol is not recommended for people with uncontrolled bronchospastic disease (e.g. current asthma symptoms) as it can block receptors that assist in opening the airways. Carvedilol may mask symptoms of low blood sugar, resulting in hypoglycemia unawareness. This is termed beta blocker induced hypoglycemia unawareness.
=== Novo Nordisk === Thomsen joined Novo Nordisk in 1991 as the head of growth hormone research. In 1994, he was appointed senior vice president of diabetes research & development. In November 2000, he became executive vice president and chief scientific officer, overseeing global operations related to drug and device research, chemistry, manufacturing and controls (CMC), global development, medical affairs, regulatory affairs, and safety. During his tenure, more than 20 pharmaceutical products were developed and approved.
1702: Pioneering English entomologist Eleanor Glanville captured a butterfly specimen in Lincolnshire, which was subsequently named the Glanville fritillary in her honour. Her extensive butterfly collection impressed fellow entomologist William Vernon, who called Glanville's work "the noblest collection of butterflies, all English, which has sham'd us". Her butterfly specimens became part of early collections in the Natural History Museum. 1702: German astronomer Maria Kirch became the first woman to discover a comet. c. 1702–1744: In Montreal, Canada, French botanist Catherine Jérémie collected plant specimens and studied their properties, sending the specimens and her detailed notes back to scientists in France. 1732: At the age of 20, Italian physicist Laura Bassi became the first female member of the Bologna Academy of Sciences. One month later, she publicly defended her academic theses and received a PhD. Bassi was awarded an honorary position as professor of physics at the University of Bologna. She was the first female physics professor in the world. 1738: French polymath Émilie du Châtelet became the first woman to have a paper published by the Paris Academy, following a contest on the nature of fire. 1740: French polymath Émilie du Châtelet published Institutions de Physique (Foundations of Physics) providing a metaphysical basis for Newtonian physics. 1748: Swedish agronomist Eva Ekeblad became the first female member of the Royal Swedish Academy of Sciences.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.